CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01935934
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:14.334563+00:00
Published At: 2020-07-14T00:00:00+00:00
Record Updated At: 2025-10-01
Results Posted At: 2020-07-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Metastatic Endometrioid Adenocarcinoma", "Recurrent Malignant Uterine Corpus Neoplasm", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Uterine Corpus Carcinosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-01"
protocolSection.identificationModule.nctId: "NCT01935934"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-07-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.